Quinidine and haloperidol as modifiers of CYP3A4 activity: Multisite kinetic model approach

Drug Metabolism and Disposition

Volumn 30, Issue 12, 2002, Pages 1512-1522

  Galetin, Aleksandra ^a   Clarke, Stephen E ^b   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; FELODIPINE; HALOPERIDOL; MIDAZOLAM; NIFEDIPINE; OXIDOREDUCTASE; QUINIDINE; SIMVASTATIN; TESTOSTERONE; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450;

ARTICLE; B LYMPHOBLAST; CONTROLLED STUDY; DRUG BINDING SITE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; INHIBITION KINETICS; MICROSOME; PRIORITY JOURNAL; STEADY STATE; BINDING SITE; BIOLOGICAL MODEL; CHEMICAL MODEL; DRUG EFFECT; DRUG INTERACTION; ENZYME ACTIVATION; ENZYMOLOGY; LIVER MICROSOME; METABOLISM; PHYSIOLOGY;

BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME ACTIVATION; HALOPERIDOL; HUMANS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MODELS, CHEMICAL; QUINIDINE;

EID: 1842866515     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.12.1512     Document Type: Article

References (38)

1. Domanski TL, HE Y-A, Harlow GR, and Halpert JR (2000) Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J Pharmacol Exp Ther 293:585-591.
2. Domanski TL, HE Y-A, Khan KK, Roussel F, Wang Q, and Halpert JR (2001) Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 40:10150-10160.
3. Feierman DE and Lasker JM (1996) Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Drug Metab Dispos 24:932-939.
4. Harlow GR and Halpert JR (1998) Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci USA 95:6636-6641.
5. Hosea NA, Miller GP, and Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
6. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
7. Ito K, Iwatsubo T, Kanamitsu S, Ueda H, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev 50:387-411.
8. Kenworthy K, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: Correlation of ten in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
9. Kenworthy KE, Clarke SE, Andrews J, and Houston JB (2001) Multi-site kinetic models for CYP3A4: Simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29:1-8.
10. Khan KK, He YQ, Domanski TL, and Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495-506.
11. Koley AP, Buters JTM, Robinson RC, Markowitz A, and Friedman FK (1995) CO binding kinetics of human cytochrome P450 3A4. J Biol Chem 270:5014-5018.
12. Koley AP, Robinson RC, Markowitz A, and Friedman FK ([997) Drug-drug interactions: Effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem Pharmacol 53:455-460.
13. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
14. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, and Shou M (2001) Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 29:368-374.
15. Lu P, Lin Y, Rodrigues AD, Rushmore TH, Baillie TA, and Shou M (2001) Testosterone, 7-benzyloxyquinoline and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4. Drug Metab Dispos 29:1473-1479.
16. Ludwig E, Jochen S, Beschke K, and Ebner T (1999) Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther 290:1-8.
17. cam. Arch Biochem Biophys 353:228-238.
18. Ngui JS, Chen Q, Shou M, Wang RW, Stearns RA, Baillie TA, and Tang W (2001) In vitro stimulation of warfarin metabolism by quinidine: Increases in the formation of 4′- and 10-hydroxywarfarin. Drug Met Dispos 29:877-886.
19. Ngui JS, Tang W, Stearns RA, Shou M, Miller RR, Zhang Y, Lin JH, and Baillie TA (2000) Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos 28:1043-1050.
20. Nielsen TL, Rasmussen BB, Flinois J-P, Beaune P, and Brøsen K (1999) In vitro metabolism of quinidine: The (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 289:31-37.
21. Pan LP, Weijnant P, De Vriendt C, Rosseel MT, and Belpaire FM (1997) Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 44:557-564.
22. Rodrigues AD, Winchell GA, and Dobrinska MR (2001) Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: The need for quantitative databases. J Clin Pharmacol 41:1-6.
23. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, and Shou M (2000) Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 30:327-343.
24. Schrag ML and Wienkers LC (2001) Triazolam substrate inhibition: Evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab Dispos 29:70-75.
25. Segel IH (1975) Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady State enzyme Systems. Wiley & Sons, Inc., New York.
26. Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, and Rushmore TH (2001a) A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem 276:2256-2262.
27. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
28. Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, et al. (2001b) Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2:17-36.
29. Shou M, Mei Q, Ettore W Jr, Dai R, Baillie T, and Rushmore TH (1999) Sigmoidal kinetic model for two cooperative substrate-binding sites in a cytochrome P450 3A4 active site: An example of the metabolism of diazepam and its derivatives. Biochem J 340:845-853.
30. Soons PA, Mulders TM, Uchida E, Schoemaker HC, Cohen AF, and Breimer DD (1993) Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: Correlation with nifedipine pharmacokinetics. Eur J Clin Pharmacol 44:163-169.
31. Stresser DM, Blanchard AP, Turner SD, Erve JCL, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
32. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. (1999) Interaction of dielofenac and quinidine in monkeys: Stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068-1074.
33. Tang W and Stearns RA (2001) Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2:185-198.
34. Tucker GT, Houston JB, and Huang S-M (2001) Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential: Toward a consensus. Clin Pharmacol Ther 70:103-114.
35. Ueng Y-F, Kuwabara T, Chun Y-J, and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
36. von Moltke LL, Greenblat DJ, Cotreau-Bibbo MM, Harmatz JS, and Shader RI (1994) Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31.
37. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AYH (2000) Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366.
38. Wang RW, Newton DJ, Scheri TD, and Lu AYH (1997) Human Cytochrome P450 3A4-catalyzed testosterone 6β-hydroxylation and erythromycin N-demethylation. Drug Metab Dispos 25:502-507.